68 research outputs found

    A Study on the Analysis and Selection of Third Party Logistics Provider for Food Companies.

    Get PDF
    Domestic food manufacturers (small and medium businesses) operate consignment operations to three-party logistics businesses for logistics efficiency while reducing logistics management elements and reducing related claims, thereby improving customer response logistics services. Recently, logistics services have a great impact on customer satisfaction and in particular, specific research on the cost impact and the factors of choosing a three-way logistics company is required. In this study, the three-way logistics company first analyzes the logistics service improvement factors by each factor based on a survey, and then qualitative and quantitative analysis on the cost savings relative to the improvement of logistics services, and analysis on the subcontractor selection factors when using the three-way logistics company services. In this study, we intend to reveal the correlation between logistics services and the factors of the company's choice through an example. | ๊ตญ๋‚ด ์‹ํ’ˆ ์ œ์กฐ์—…์ฒด(์ค‘์†Œ๊ธฐ์—…)์—์„œ๋Š” ๋ฌผ๋ฅ˜๋น„์šฉ์„ ์ค„์ด๋ฉฐ ๋ฌผ๋ฅ˜ํšจ์œจํ™”๋ฅผ ์œ„ํ•˜์—ฌ 3์ž ๋ฌผ๋ฅ˜ ๊ธฐ์—…์—๊ฒŒ ์œ„ํƒ์šด์˜์„ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ด๋กœ์จ, ๋ฌผ๋ฅ˜ ๊ด€๋ฆฌ์š”์†Œ ๊ฐ์†Œ ๋ฐ ๊ด€๋ จ ํด๋ ˆ์ž„ ์ €๊ฐ ๋“ฑ์œผ๋กœ ๊ณ ๊ฐ ๋Œ€์‘ ๋ฌผ๋ฅ˜ ์„œ๋น„์Šค๋ฅผ ํ–ฅ์ƒ์‹œํ‚ค๊ณ  ์žˆ๋‹ค. ์ตœ๊ทผ ๋ฌผ๋ฅ˜์„œ๋น„์Šค๊ฐ€ ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋งŽ์€ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋ฉฐ ํŠนํžˆ, ๋น„์šฉ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ๊ณผ 3์ž ๋ฌผ๋ฅ˜์‚ฌ ์„ ํƒ ์š”์ธ์— ๊ด€ํ•œ ๊ตฌ์ฒด์ ์ธ ์—ฐ๊ตฌ๊ฐ€ ํ•„์š”ํ•œ ์‹ค์ •์ด๋‹ค ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ๋จผ์ €, 3์ž ๋ฌผ๋ฅ˜ ๊ธฐ์—…์˜ ๋ฌผ๋ฅ˜ ์„œ๋น„์Šค ํ–ฅ์ƒ ์š”์ธ์— ๋Œ€ํ•˜์—ฌ ์„ค๋ฌธ์„ ๋ฐ”ํƒ•์œผ๋กœ ๊ฐ ์š”์ธ๋ณ„๋กœ ๋ถ„์„์„ ํ–‰ํ•˜๋ฉฐ, ๋ฌผ๋ฅ˜์„œ๋น„์Šค ํ–ฅ์ƒ ๋Œ€๋น„ ๋น„์šฉ์ ˆ๊ฐ ํšจ๊ณผ์— ๋Œ€ํ•ด ์ •์„ฑ์ , ์ •๋Ÿ‰์ ์ธ ๋ถ„์„๊ณผ 3์ž ๋ฌผ๋ฅ˜์‚ฌ ์„œ๋น„์Šค ์ด์šฉ ์‹œ ์—…์ฒด ์„ ํƒ ์š”์ธ์— ๋Œ€ํ•ด ๋ถ„์„์„ ํ–‰ํ•˜๊ณ ์ž ํ•œ๋‹ค. ์ด์— ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” S์‚ฌ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋ฌผ๋ฅ˜ ์„œ๋น„์Šค์™€ ๊ธฐ์—…์˜ ์„ ํƒ ์š”์ธ์— ๋Œ€ํ•œ ์ƒ๊ด€๊ด€๊ณ„๋ฅผ ์‚ฌ๋ก€๋ฅผ ํ†ตํ•˜์—ฌ ๋ฐํžˆ๊ณ ์ž ํ•œ๋‹ค.๋ชฉ ์ฐจ List of Tables โ…ฒ List of Figures โ…ด ๊ตญ๋ฌธ์ดˆ๋ก โ…ต Abstract โ…ถ ์ œ 1 ์žฅ ์„œ ๋ก  1 1.1 ์—ฐ๊ตฌ๋ฐฐ๊ฒฝ 1 1.2 ์—ฐ๊ตฌ๋ชฉ์  2 1.3 ์—ฐ๊ตฌ๋‚ด์šฉ ๋ฐ ๋ฐฉ๋ฒ• 2 ์ œ 2 ์žฅ 3์ž ๋ฌผ๋ฅ˜์™€ 3์ž ๋ฌผ๋ฅ˜ ๊ธฐ์—… ํ˜„ํ™ฉ 4 2.1 3์ž ๋ฌผ๋ฅ˜์˜ ๊ฐœ๋… 4 2.2 3์ž ๋ฌผ๋ฅ˜์˜ ๋“ฑ์žฅ๋ฐฐ๊ฒฝ 5 2.3 3์ž ๋ฌผ๋ฅ˜์˜ ํŠน์ง• 6 2.4 3์ž ๋ฌผ๋ฅ˜์˜ ํšจ๊ณผ 7 2.5 ๊ตญ๋‚ด 3์ž ๋ฌผ๋ฅ˜ ๊ธฐ์—… ํ˜„ํ™ฉ 8 ์ œ 3 ์žฅ ๋ฌผ๋ฅ˜์„œ๋น„์Šค ํ’ˆ์งˆ์˜ ์ •์˜ ๋ฐ ์ด๋ก ์  ๊ณ ์ฐฐ 29 3.1 ์„œ๋น„์Šค ํ’ˆ์งˆ 29 3.2 ๋ฌผ๋ฅ˜์„œ๋น„์Šค ํ’ˆ์งˆ์˜ ๊ฐœ๋… 30 3.3 ๋ฌผ๋ฅ˜์„œ๋น„์Šค ํ’ˆ์งˆ์˜ ๊ตฌ์„ฑ์š”์ธ 32 ์ œ 4 ์žฅ 3์ž๋ฌผ๋ฅ˜ ๊ธฐ์—…์˜ ๋ฌผ๋ฅ˜์„œ๋น„์Šค ์š”์ธ ๋ถ„์„ 35 4.1 ๋ฌผ๋ฅ˜์„œ๋น„์Šค ์š”์ธ ์ธก์ •๋„๊ตฌ 35 4.2 ์„ค๋ฌธ์กฐ์‚ฌ ๋‚ด์šฉ ๋ฐ ๋ฐฉ๋ฒ• 40 4.3 ์„ค๋ฌธ์กฐ์‚ฌ ๋ถ„์„ ๊ฒฐ๊ณผ 42 ์ œ 5 ์žฅ ์‚ฌ๋ก€์— ์˜ํ•œ 3์ž ๋ฌผ๋ฅ˜์‚ฌ ์„ ํƒ ์š”์ธ ๋ถ„์„ 52 5.1 ์‚ฌ๋ก€๊ธฐ์—… ์†Œ๊ฐœ 52 5.2 S์‚ฌ ๋ฌผ๋ฅ˜ ํ๋ฆ„ FLOW 52 5.3 S์‚ฌ ๋ฌผ๋ฅ˜ ๊ฐœ์„  ํšจ๊ณผ์— ๋Œ€ํ•œ ์ •์„ฑ์ , ์ •๋Ÿ‰์  ๋ถ„์„ 53 5.4 S์‚ฌ์˜ 3์ž ๋ฌผ๋ฅ˜ ์„œ๋น„์Šค ์ด์šฉ ํ›„ ๋ณ€ํ™” ์ถ”์ด 59 5.5 S์‚ฌ์˜ 3์ž ๋ฌผ๋ฅ˜ ์„œ๋น„์Šค ์„ ํƒ ์š”์ธ 61 ์ œ 6 ์žฅ ๊ฒฐ ๋ก  62 6.1 ๊ฒฐ๋ก  62 6.2 ์—ฐ๊ตฌ์˜ ํ•œ๊ณ„์  ๋ฐ ๊ณผ์ œ 64 ์ฐธ๊ณ ๋ฌธํ—Œ 65 ๋ณ„์ฒจ 70Maste

    a new property of the protein.

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2017. 8. ๊ณฝ์˜ํ˜ธ.์„œ๋ก : ํŒจํ˜ˆ์ฆ์€ ์ „ ์„ธ๊ณ„์ ์œผ๋กœ ๋†’์€ ์‚ฌ๋ง๋ฅ ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋Š” ์งˆํ™˜์œผ๋กœ ์•”, ๊ธ‰์„ฑ ์‹ฌ์žฅ์‚ฌ ๋“ฑ์— ์ด์€ ์ค‘์š”ํ•œ ์‚ฌ๋ง ์›์ธ ์ค‘์˜ ํ•˜๋‚˜๋กœ ์‚ฌํšŒ, ๊ฒฝ์ œ์ ์œผ๋กœ ํฐ ์†์‹ค์„ ์œ ๋ฐœํ•˜๊ณ  ์žˆ๋‹ค. ์ตœ๊ทผ ์—ฐ๊ตฌ์— ์˜ํ•˜๋ฉด ํŒจํ˜ˆ์ฆ ์‹œ์— ์šฉํ˜ˆ ๋ฐ˜์‘์ด ๊ด‘๋ฒ”์œ„ํ•˜๊ฒŒ ์ผ์–ด๋‚˜๋ฉฐ, ์šฉํ˜ˆ ๋ฐ˜์‘์„ ํ†ตํ•ด ์ƒ์„ฑ๋œ ํ—ด (heme)์— ์˜ํ•ด ์‚ฐํ™” ๋ฐ˜์‘๊ณผ ์—ผ์ฆ ๋ฐ˜์‘์ด ๊ฐ€์†ํ™”๋˜๊ณ  ๊ฒฐ๊ณผ์ ์œผ๋กœ ์‹ฌํ•œ ์กฐ์ง ์†์ƒ์„ ์ผ์œผํ‚จ๋‹ค๊ณ  ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ํ—ค๋ชจํŽ™์‹  (hemopexin, HPX)์€ ์œ ๋ฆฌ ํ—ด (free heme)์„ ํ˜ˆ์ค‘ ๋ฐ ์กฐ์ง์—์„œ ํฌํ•ฉํ•˜์—ฌ ๊ฐ„์„ธํฌ ๋‚ด๋กœ ์ด๋™์‹œํ‚จ ํ›„ ์ œ๊ฑฐํ•˜๋Š” ์ฒญ์†Œ(scavenger) ๋‹จ๋ฐฑ์งˆ๋กœ์„œ ํ—ด์— ์˜ํ•œ ์—ผ์ฆ ๋ฐ˜์‘์„ ์ค„์—ฌ์ค„ ์ˆ˜ ์žˆ๋Š” ํ›„๋ณด๋ฌผ์งˆ๋กœ ์ตœ๊ทผ ์ฃผ๋ชฉ๋ฐ›๊ณ  ์žˆ๋‹ค. ํ•˜์ง€๋งŒ ์•„์ง ํŒจํ˜ˆ์ฆ์ด๋‚˜ ๋‚ด๋…์†Œํ˜ˆ์ฆ(endotoxemia)์—์„œ ํ—ค๋ชจํŽ™์‹ ์˜ ์—ญํ• ์ด ๋ช…ํ™•ํ•˜๊ฒŒ ๋ฐํ˜€์ง€์ง€ ์•Š๊ณ  ์žˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” ๋‚ด๋…์†Œํ˜ˆ์ฆ์„ ์œ ๋ฐœํ•œ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ ํ•ญ์—ผ์ฆ ํšจ๊ณผ๋ฅผ ๋ณด์ผ ๊ฒƒ์œผ๋กœ ๊ธฐ๋Œ€๋˜๋Š” ํ—ค๋ชจํŽ™์‹ ์˜ ํˆฌ์—ฌ๊ฐ€ ๋งˆ์šฐ์Šค์˜ ์ „์‹  ๋ฐ ํ์กฐ์ง์˜ ์—ผ์ฆ ๋ฐ˜์‘์„ ๊ฐ์†Œ์‹œํ‚ค๋Š”์ง€ ์•Œ์•„๋ณด์•˜๋‹ค. ๋ฐฉ๋ฒ•: ์ˆ˜์ปท ๋งˆ์šฐ์Šค(20-23g)์— lipopolysaccharide (LPS)๋ฅผ ์ •๋งฅ์„ ํ†ตํ•˜์—ฌ ์ฃผ์ž…ํ•˜์—ฌ ๋‚ด๋…์†Œํ˜ˆ์ฆ์„ ์œ ๋ฐœํ•˜์˜€๋‹ค. LPS์˜ ์–‘์€ ์‚ฌ์ „ ์‹คํ—˜์„ ํ†ตํ•˜์—ฌ 75%์˜ ์‚ฌ๋ง๋ฅ ์„ ๋ณด์ด๋Š” 10 mg/kg ์˜ ์šฉ๋Ÿ‰์„ ์‚ฌ์šฉํ•˜์˜€๊ณ , ํ–ฅํ›„ ํˆฌ์—ฌํ•  ํ—ค๋ชจํŽ™์‹  (hemopexin, HPX) ์šฉ๋Ÿ‰์€ ๊ธฐ์กด ์—ฐ๊ตฌ๋ฅผ ์ฐธ๊ณ ํ•˜์—ฌ 5 mg/kg๋กœ ๊ฒฐ์ •ํ•˜์˜€๋‹ค. ๋Œ€์กฐ๊ตฐ, LPS๊ตฐ (LPS treated only), LPS+HPX๊ตฐ (HPX supplement after LPS-treated)์˜ ์„ธ ๊ฐœ ๊ตฐ์œผ๋กœ ๋‚˜๋ˆ„์–ด ์ƒ์กด ์‹คํ—˜์„ ์ง„ํ–‰ํ•˜์˜€๋‹ค. ๋Œ€์กฐ๊ตฐ์˜ ๊ฒฝ์šฐ ๋ณต๊ฐ• ๋‚ด๋กœ ์ƒ๋ฆฌ์‹์—ผ์ˆ˜, ์ •๋งฅ์œผ๋กœ ์ฆ๋ฅ˜์ˆ˜๋ฅผ ํˆฌ์—ฌํ•˜์˜€๋‹ค. ๋‚˜๋จธ์ง€ ๊ตฐ๋“ค์€ ๋งˆ์šฐ์Šค์˜ ๋ณต๊ฐ• ๋‚ด๋กœ LPS๋ฅผ ํˆฌ์—ฌํ•˜์—ฌ ๋‚ด๋…์†Œํ˜ˆ์ฆ์„ ์œ ๋ฐœํ•œ ํ›„ 30๋ถ„ ํ›„์— ์ •๋งฅ์œผ๋กœ ์ฆ๋ฅ˜์ˆ˜ (LPS๊ตฐ), ํ—ค๋ชจํŽ™์‹  (LPS+HPX๊ตฐ)์„ ํˆฌ์—ฌํ•˜์˜€๋‹ค. ์ดํ›„ 36์‹œ๊ฐ„ ๋™์•ˆ ์ƒ์กด ์—ฌ๋ถ€๋ฅผ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ๋˜ ๋‹ค๋ฅธ ์‹คํ—˜์œผ๋กœ ์ƒ์กด ์‹คํ—˜๊ณผ ๊ฐ™์€ ํ™˜๊ฒฝ ๋ฐ ์กฐ์ž‘์„ ๊ฐ€ํ•˜๊ณ  ์„ธ ๊ตฐ์—์„œ 0์‹œ๊ฐ„, 3์‹œ๊ฐ„, 6์‹œ๊ฐ„์— ๋งˆ์šฐ์Šค๋ฅผ ์‹ฌ์žฅ์ฑ„ํ˜ˆ์„ ํ†ตํ•ด ํฌ์ƒ์‹œํ‚จ ํ›„ ํ˜ˆ์ค‘ tumor necrosis factor-ฮฑ (TNF-ฮฑ), interleukin-6 (IL-6) ๋ฐ HPX ๋†๋„๋ฅผ ์‹œ๊ฐ„๋Œ€ ๋ณ„๋กœ ์ธก์ •ํ•˜์˜€๋‹ค. ๋˜ํ•œ ํ์กฐ์ง์„ ๋ถ„๋ฆฌํ•˜์—ฌ 0์‹œ๊ฐ„, 3์‹œ๊ฐ„, 6์‹œ๊ฐ„ ์‹œ์ ์˜ cytoplasmic inhibitor ฮบB-ฮฑ (IฮบB-ฮฑ), nuclear factor-ฮบB (NF-ฮบB), and the NF-ฮบB์˜ p65 subunit (NF-ฮบB p65)๋ฅผ ์ธก์ •ํ•˜๊ณ  6์‹œ๊ฐ„ ํ›„ ๊ฐ ๊ตฐ์˜ ์กฐ์งํ•™์  ํŠน์„ฑ์„ Haematoxylin and eosin ์—ผ์ƒ‰๊ณผ ํ ์†์ƒ ์ ์ˆ˜๋ฅผ ํ†ตํ•ด ๋น„๊ตํ•˜์˜€๋‹ค. ๊ฐ ํ•ญ๋ชฉ์˜ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ๋ณ€ํ™” ๋ถ„์„์€ one-way repeated measured analysis of variance ๋ฐฉ๋ฒ•์œผ๋กœ ๋น„๊ตํ•˜์˜€๊ณ  ์‹œ๊ฐ„๋Œ€๋ณ„ ๊ฐ ๊ตฐ์˜ ์ฐจ์ด์— ๋Œ€ํ•œ ๋ถ„์„์€ Mann-Whitney U post hoc test with Bonferroni correction ๋ฐฉ๋ฒ•์„ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„์„ํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ: ์ƒ์กด์‹คํ—˜ ๊ฒฐ๊ณผ ๋Œ€์กฐ๊ตฐ์€ ๋ชจ๋‘ ์ƒ์กดํ•˜์˜€์œผ๋ฉฐ LPS๊ตฐ์€ 63.6%, LPS+HPX๊ตฐ์€ 9.1%์˜ ์‚ฌ๋ง๋ฅ ์„ ๋ณด์—ฌ LPS๊ตฐ์— ๋น„ํ•ด LPS+HPX ๊ตฐ์ด ์œ ์˜ํ•˜๊ฒŒ ์‚ฌ๋ง๋ฅ ์ด ๋‚ฎ์•˜๋‹ค. (p <0.05) ํ˜ˆ์ค‘ TNF-ฮฑ ์™€ IL-6 ๋Š” 3์‹œ๊ฐ„๊ณผ 6์‹œ๊ฐ„์— LPS+HPX ๊ตฐ์—์„œ LPS๊ตฐ์— ๋น„ํ•ด ์œ ์˜ํ•˜๊ฒŒ ๋‚ฎ์€ ๊ฒฐ๊ณผ๋ฅผ ๋ณด์˜€๋‹ค. (p <0.05) ๋˜ํ•œ LPS๊ตฐ์— ๋น„ํ•ด LPS+HPX๊ตฐ์˜ cytoplasmic p-IฮบB-ฮฑ, NF-ฮบB p65 expression์€ LPS๊ตฐ์— ๋น„ํ•ด ์œ ์˜ํ•˜๊ฒŒ ์ฆ๊ฐ€๋˜์—ˆ๋‹ค. (p=0.017) NF-ฮบB p65 binding activity์™€ cytoplasmic p-IฮบB-ฮฑ ๋Œ€ IฮบB-ฮฑ ratio ์—ญ์‹œ LPS+HPX๊ตฐ์—์„œ LPS๊ตฐ์— ๋น„ํ•ด ์œ ์˜ํ•˜๊ฒŒ ๋‚ฎ์•˜๋‹ค. (p=0.002) 6์‹œ๊ฐ„์งธ ์กฐ์งํ•™์  ๊ฒฐ๊ณผ ๋ฐ ํ ์†์ƒ ์ ์ˆ˜์—์„œ๋„ LPS๊ตฐ์— ๋น„ํ•ด LPS+HPX๊ตฐ์—์„œ ์œ ์˜ํ•˜๊ฒŒ ํ ์†์ƒ์ด ์ ์€ ๊ฒฐ๊ณผ๋ฅผ ๋ณด์—ฌ์ฃผ์—ˆ๋‹ค. ๊ฒฐ๋ก : ๋‚ด๋…์†Œํ˜ˆ์ฆ์„ ์œ ๋ฐœํ•œ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ ํ—ค๋ชจํŽ™์‹ ์˜ ์ฃผ์ž…์€ ์ „์‹  ์—ผ์ฆ ๋ฐ˜์‘์„ ์ค„์ด๊ณ  ํ์กฐ์ง์—์„œ ํ ์†์ƒ์„ ์ค„์—ฌ ์ฃผ๋ฉฐ ์ƒ์กด์œจ์„ ์ฆ๊ฐ€์‹œ์ผฐ๋‹ค. ์ด ํšจ๊ณผ๋Š” NF-ฮบB pathway์˜ ์–ต์ œ์™€ ๋ฐ€์ ‘ํ•œ ๊ด€๋ จ์ด ์žˆ์„ ๊ฒƒ์œผ๋กœ ํŒ๋‹จ๋œ๋‹ค.์„œ๋ก  1 1. ์—ฐ๊ตฌ ๋ฐฐ๊ฒฝ . 1 1) ํŒจํ˜ˆ์ฆ์˜ ํ˜„ํ™ฉ ๋ฐ ๋ฌธ์ œ์  1 2) ํŒจํ˜ˆ์ฆ์˜ ์•Œ๋ ค์ง„ ๊ธฐ์ „๊ณผ ์—ผ์ฆ ๋ฐ˜์‘ 2 3) Nuclear kappa B pathway 5 4) ํŒจํ˜ˆ์ฆ์—์„œ์˜ ํ ์กฐ์ง์†์ƒ 8 5) ํŒจํ˜ˆ์ฆ ํ™˜์ž์˜ ์น˜๋ฃŒ ๋ฐฉ์นจ ๋ฐ ๋ฌธ์ œ์  9 6) ํŒจํ˜ˆ์ฆ์—์„œ free heme(ํ—ด)์˜ ์—ญํ•  10 7) ํ—ค๋ชจํŽ™์‹ (hemopexin) ๋ฐ ์—ญํ•  12 2. ํ•„์š”์„ฑ . 14 3. ์—ฐ๊ตฌ ๊ฐ€์„ค 15 4. ์—ฐ๊ตฌ ๋ชฉ์  17 ์—ฐ๊ตฌ ์žฌ๋ฃŒ ๋ฐ ๋ฐฉ๋ฒ• 18 1. ์—ฐ๊ตฌ ์žฌ๋ฃŒ 18 1) ์‹คํ—˜๋™๋ฌผ์˜ ํš๋“๊ณผ ์ˆœํ™” ๊ณผ์ • 18 2) ์‹คํ—˜๊ตฐ ์„ค์ • 19 3) ์‹คํ—˜์•ฝ ์„ค์ • 19 2. ์—ฐ๊ตฌ ๋ฐฉ๋ฒ• . 20 1) ์‹คํ—˜๋™๋ฌผ์˜ ๋งˆ์ทจ์™€ ์ค€๋น„ 20 2๏ผ‰๋‚ด๋…์†Œํ˜ˆ์ฆ ์œ ๋„ ๋ฐ ์ƒ์กด์‹คํ—˜ 20 3) ๋‚ด๋…์†Œํ˜ˆ์ฆ ์œ ๋„ ๋ฐ ํ—ค๋ชจํŽ™์‹  ๋ณด์ถฉ ์‹คํ—˜ 21 4) ํ—ค๋ชจํŽ™์‹  ํˆฌ์—ฌ๋Ÿ‰์˜ ๊ฒฐ์ • 25 3. ๊ฒฐ๊ณผ์ง€ํ‘œ์˜ ์ธก์ • 26 1) ๊ฒ€์ฒด ์ฑ„์ทจ 26 2) Enzyme-linked immunosorbent assays 26 3) ํ์กฐ์ง์˜ ํš๋“ 27 4) Western blot analysis and NF-kB binding activity 27 5) ๋ณ‘๋ฆฌ์กฐ์งํ•™์  ๊ฒฐ๊ณผ์˜ ์ธก์ • 29 4. ๊ฒฐ๊ณผ์˜ ๋ถ„์„ 32 ์—ฐ๊ตฌ ๊ฒฐ๊ณผ 33 1. ์ƒ์กด์œจ ๊ฒฐ๊ณผ 33 2. ํ˜ˆ์ค‘ ํ—ค๋ชจํŽ™์‹  ๋ฐ ์—ผ์ฆ cytokine ๋†๋„ ์ธก์ • ๊ฒฐ๊ณผ 35 1) Serum hemopexin level 35 2) Tumor necrosis factor alpha level 38 3) Interleukin 6 level 40 4. Tissue assay and Western blot ๊ฒฐ๊ณผ 42 1) Western blot ๊ฒฐ๊ณผ 42 2) Nuclear factor kappa-B transcription factor assays 46 5. ๋ณ‘๋ฆฌ ์กฐ์งํ•™์  ๊ฒฐ๊ณผ 48 1) Haematoxylin and eosin stain 48 2) Lung injury score 50 ๊ณ ์ฐฐ 52 ๊ฒฐ๋ก  60 ์ฐธ๊ณ ๋ฌธํ—Œ 61 ์ดˆ๋ก (์˜๋ฌธ) 67Docto

    ์‹œ์žฅํ˜•ยท์ค€์‹œ์žฅํ˜• ๊ณต๊ธฐ์—… ์ค‘์‹ฌ์œผ๋กœ

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ) -- ์„œ์šธ๋Œ€ํ•™๊ต๋Œ€ํ•™์› : ํ–‰์ •๋Œ€ํ•™์› ๊ณต๊ธฐ์—…์ •์ฑ…ํ•™๊ณผ, 2022. 8. ๊น€๋ณ‘์กฐ.The purpose of this study is to investigate the correlation between the level of integrity of public companies and the management performance of companies. As Korea grows, the public's eye level and their requirements are increasing, and accordingly, the 'integrity' of public enterprises is being emphasized more. Nevertheless, it is a natural responsibility to regard the value of "integrity" as a public enterprise while many recent cases occur which greatly undermine the credibility of the public sector, such as speculation in real estates using internal information. As public enterprises account for a large portion of the Korean economy, they should be a driving force that drives national economic growth through ethical and transparent corporate management. However, the profitability of companies to pursue profits must be guaranteed. Publicity and profitability are not alternative concepts, but they could be a hindrance to pursuing profitability. Therefore, by proving to pursue the publicity 'integrity' becomes a foundation for sustainable growth in the long term, it was intended to explain that it was a necessary choice for the growth and development of companies, not public companies. The subjects of the study were 16 market-type public enterprises and 20 quasi-market-type public enterprises among public enterprises prescribed by the law โ€˜Public Institution Operation Actโ€™. And the measurement period was for 10 years from 2011 to 2020. The variables used in this study are as follows. As an independent variable, an integrity index announced by the National Rights Commission was established. It was subdivided into comprehensive integrity, external integrity, and internal integrity. The dependent variables were divided into financial performance indicators and non-financial performance indicators, which were profitability indicators, pre-tax returns, stability indicators, interest compensation ratios, and total asset turnover indicators. As a non-financial performance indicator, the results of the customer satisfaction survey announced by the Ministry of Strategy and Finance were used. Sales, average annual salary, and type of public enterprise were set as control variables. As an adjustment variable, the correlation was checked under what conditions the correlation changed by setting the female employee ratio and the company type by customer characteristics (B2C/B2B). First, it was not confirmed that the level of integrity of public companies necessarily had a positive effect on financial performance. This is believed to be due to the fact that public corporations are in a special position that cannot respond quickly to the market and pursue efficiency only. Second, it was confirmed that internal integrity had a significant positive (+) correlation with customer satisfaction. It is estimated that the 'integrity' mindset and transparent business processing of internal members ultimately have a positive effect on the company's external customers Third, it was confirmed that the ratio of female employees had a negative effect on the correlation between the level of integrity and corporate management performance. In particular, it was confirmed that the higher the ratio of female employees, the stronger the negative effect or the weaker the positive effect on the relationship between comprehensive integrity, internal integrity, and customer satisfaction. This can be inferred that external customers who aim to maximize their profit will demand prompt and flexible work, and due to the nature of female employees less involved in corruption, conflicts occur in this process, which negatively affected customer satisfaction. Finally, significant results were not obtained on the effect of corporate types by customer characteristics on the correlation between the level of integrity and corporate management performance. The closer it is to a B2C company, the more it is to engage in sales activities with an unspecified number of customers, which is judged to result in a positive effect by generously investing in the company's human and material resources to improve customer satisfaction, but there is no particular correlation. In conclusion, although it failed to produce a result that guarantees the management performance of a company with a high level of integrity, I think this study is meaningful in that at least it proved the level of integrity is not a unmeaningful relationship with the company's management performance.๋ณธ ์—ฐ๊ตฌ์˜ ๋ชฉ์ ์€ ๊ณต๊ธฐ์—…์˜ ์ฒญ๋ ด๋„ ์ˆ˜์ค€๊ณผ ๊ธฐ์—…์˜ ๊ฒฝ์˜์„ฑ๊ณผ๊ฐ„์— ์–ด๋– ํ•œ ์ƒ๊ด€๊ด€๊ณ„๊ฐ€ ์žˆ๋Š”์ง€ ์•Œ์•„๋ณด๊ณ ์ž ํ•˜๋Š” ๊ฒƒ์ด๋‹ค. ์šฐ๋ฆฌ๋‚˜๋ผ๊ฐ€ ์„ฑ์žฅํ•จ์— ๋”ฐ๋ผ ๊ตญ๋ฏผ์˜ ๋ˆˆ๋†’์ด์™€ ์š”๊ตฌ์‚ฌํ•ญ์€ ์ ์  ๋†’์•„์ง€๊ณ  ์ด์— ๋”ฐ๋ผ ๊ณต๊ธฐ์—…์˜ โ€˜์ฒญ๋ ดโ€™์€ ๋”์šฑ ๊ฐ•์กฐ๋˜๊ณ  ์žˆ๋‹ค. ๊ทธ๋Ÿผ์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ์ตœ๊ทผ ์ผ๋ถ€ ๊ณต๊ธฐ์—…์—์„œ ๋‚ด๋ถ€์ •๋ณด๋ฅผ ์ด์šฉํ•œ ํˆฌ๊ธฐ ์‚ฌ๊ฑด ๋“ฑ ๊ณต๊ณต๋ถ€๋ฌธ์˜ ์‹ ๋ขฐ์„ฑ์„ ํฌ๊ฒŒ ํ›ผ์†ํ•˜๋Š” ์‚ฌ๋ก€๋Š” ์ง€์†์ ์œผ๋กœ ๋ฐœ์ƒํ•˜๋Š” ๊ฐ€์šด๋ฐ ๊ตญ๋ฏผ์˜ ๊ธฐ์—…์ธ ๊ณต๊ธฐ์—…์œผ๋กœ์„œ โ€˜์ฒญ๋ ดโ€™์˜ ๊ฐ€์น˜๋ฅผ ์ค‘์š”์‹œ ์—ฌ๊ธฐ๋Š” ๊ฒƒ์€ ์–ด๋–ป๊ฒŒ ๋ณด๋ฉด ๋‹น์—ฐํ•œ ์ฑ…๋ฌด๋ผ๊ณ  ์ƒ๊ฐ๋œ๋‹ค. ๊ณต๊ธฐ์—…์ด ์šฐ๋ฆฌ๋‚˜๋ผ ๊ฒฝ์ œ์—์„œ ํฐ ๋น„์ค‘์„ ์ฐจ์ง€ํ•˜๋Š” ๋งŒํผ ์œค๋ฆฌ์ ์ด๊ณ  ํˆฌ๋ช…ํ•œ ๊ธฐ์—…๊ฒฝ์˜์„ ํ†ตํ•ด ๊ตญ๊ฐ€ ๊ฒฝ์ œ์„ฑ์žฅ์„ ๊ฒฌ์ธํ•˜๋Š” ์—ญ๊ตฐ์ด ๋˜์–ด์•ผ ํ•œ๋‹ค. ํ•˜์ง€๋งŒ ๊ธฐ์—…์€ ์ƒ์กด์„ ์œ„ํ•ด ์ด์œค์„ ์ถ”๊ตฌํ•ด์•ผ ํ•˜๋Š”, ์ฆ‰ ์ˆ˜์ต์„ฑ์ด ๋‹ด๋ณด๋˜์–ด์•ผ ํ•œ๋‹ค. ๊ณต๊ณต์„ฑ๊ณผ ์ˆ˜์ต์„ฑ์€ ๋Œ€์น˜๋˜๋Š” ๊ฐœ๋…์€ ์•„๋‹ˆ์ง€๋งŒ ์ˆ˜์ต์„ฑ์„ ์ถ”๊ตฌํ•˜๋Š”๋ฐ ์ €ํ•ด์š”์†Œ๊ฐ€ ๋˜๊ธฐ๋„ ํ•œ๋‹ค. ๋”ฐ๋ผ์„œ โ€˜์ฒญ๋ ดโ€™์ด๋ผ๋Š” ๊ณต๊ณต์„ฑ, ๊ณต์ต์„ฑ์„ ์ถ”๊ตฌํ•˜๋Š” ๊ฒƒ์ด ์žฅ๊ธฐ์ ์œผ๋กœ๋Š” ์ง€์†๊ฐ€๋Šฅํ•œ ์„ฑ์žฅ์„ ์œ„ํ•œ ๋ฐ˜์„์ด ๋œ๋‹ค๋Š” ๊ฒƒ์„ ์ž…์ฆํ•จ์œผ๋กœ์„œ ๊ณต๊ธฐ์—…์ด๋ผ์„œ๊ฐ€ ์•„๋‹Œ ๊ธฐ์—…์˜ ์„ฑ์žฅ๊ณผ ๋ฐœ์ „์„ ์œ„ํ•ด ๋‹น์—ฐํ•œ ์„ ํƒ์ž„์„ ์„ค๋ช…ํ•˜๊ณ ์ž ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ๋Œ€์ƒ์œผ๋กœ๋Š” โ€˜๊ณต๊ณต๊ธฐ๊ด€ ์šด์˜์— ๊ด€ํ•œ ๋ฒ•๋ฅ โ€™์ด ๊ทœ์ •ํ•˜๋Š” ๊ณต๊ธฐ์—… ์ค‘ ์‹œ์žฅํ˜•๊ณต๊ธฐ์—… 16๊ฐœ์™€ ์ค€์‹œ์žฅํ˜•๊ณต๊ธฐ์—… 20๊ฐœ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€๋‹ค. ๊ทธ๋ฆฌ๊ณ  ์ธก์ •๊ธฐ๊ฐ„์€ 2011๋…„๋ถ€ํ„ฐ 2020๋…„๊นŒ์ง€ 10๊ฐœ๋…„๋„๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€๋‹ค. ๋ณธ ์—ฐ๊ตฌ์—์„œ ์‚ฌ์šฉ๋œ ๋ณ€์ˆ˜๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™๋‹ค. ๋…๋ฆฝ๋ณ€์ˆ˜๋กœ๋Š” ๊ตญ๋ฏผ๊ถŒ์ต์œ„์›ํšŒ์—์„œ ๊ณต์‹œํ•˜๋Š” ์ฒญ๋ ด๋„์ง€ํ‘œ๋ฅผ ์„ค์ •ํ•˜์˜€๋‹ค. ์ข…ํ•ฉ์ฒญ๋ ด๋„, ์™ธ๋ถ€์ฒญ๋ ด๋„, ๋‚ด๋ถ€์ฒญ๋ ด๋„๋กœ ์„ธ๋ถ„ํ™”ํ•˜์˜€๋‹ค. ์ข…์†๋ณ€์ˆ˜๋กœ๋Š” ์žฌ๋ฌด์  ์„ฑ๊ณผ์ง€ํ‘œ์™€ ๋น„์žฌ๋ฌด์  ์„ฑ๊ณผ์ง€ํ‘œ๋กœ ๋‚˜๋ˆ„์—ˆ๋Š”๋ฐ, ์žฌ๋ฌด์  ์„ฑ๊ณผ์ง€ํ‘œ๋กœ๋Š” ์ˆ˜์ต์„ฑ์ง€ํ‘œ์ธ ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ , ์•ˆ์ •์„ฑ์ง€ํ‘œ์ธ ์ด์ž๋ณด์ƒ๋ฐฐ์œจ ๊ทธ๋ฆฌ๊ณ  ํ™œ๋™์„ฑ์ง€ํ‘œ๋กœ๋Š” ์ด์ž์‚ฐํšŒ์ „์œจ์„ ์„ค์ •ํ•˜์˜€๋‹ค. ๋น„์žฌ๋ฌด์  ์„ฑ๊ณผ์ง€ํ‘œ๋กœ๋Š” ๊ธฐํš์žฌ์ •๋ถ€์—์„œ ๊ณต์‹œํ•˜๋Š” ๊ณ ๊ฐ๋งŒ์กฑ๋„ ์กฐ์‚ฌ๊ฒฐ๊ณผ๋ฅผ ํ™œ์šฉํ•˜์˜€๋‹ค. ํ†ต์ œ๋ณ€์ˆ˜๋กœ๋Š” ๋งค์ถœ์•ก, ํ‰๊ท ์—ฐ๋ด‰, ๊ณต๊ธฐ์—…์œ ํ˜•์„ ์„ค์ •ํ•˜์˜€๋‹ค. ์กฐ์ ˆ๋ณ€์ˆ˜๋กœ๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ๊ณผ ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜•(B2C/B2B)๋ฅผ ์„ค์ •ํ•˜์—ฌ ์–ด๋– ํ•œ ์กฐ๊ฑด์—์„œ ์ƒ๊ด€๊ด€๊ณ„๊ฐ€ ๋ณ€ํ•˜๋Š”์ง€ ํ™•์ธํ•ด๋ณด๊ณ ์ž ํ•˜์˜€๋‹ค. ์ฒซ์งธ, ๊ณต๊ธฐ์—…์˜ ์ฒญ๋ ด๋„ ์ˆ˜์ค€์ด ์žฌ๋ฌด์  ์„ฑ๊ณผ์— ๋ฐ˜๋“œ์‹œ ๊ธ์ •์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค๋Š” ์‚ฌ์‹ค์€ ํ™•์ธํ•˜์ง€ ๋ชปํ–ˆ๋‹ค. ์ด๋Š” ๊ณต๊ณต์„ฑ์„ ์ถ”๊ตฌํ•˜๋Š” ๊ณต๊ธฐ์—…์˜ ์ž…์žฅ์—์„œ ์‹œ์žฅ์— ๊ธฐ๋ฏผํ•˜๊ฒŒ ๋Œ€์‘ํ•˜๊ณ  ํšจ์œจ์„ฑ๋งŒ์„ ์ถ”๊ตฌํ•  ์ˆ˜ ์—†๋Š” ํŠน์ˆ˜ํ•œ ์ง€์œ„์— ์žˆ๊ธฐ ๋•Œ๋ฌธ์ด๋ผ๊ณ  ์ƒ๊ฐ๋œ๋‹ค. ๋‘ ๋ฒˆ์งธ, ๋‚ด๋ถ€์ฒญ๋ ด๋„๋Š” ๊ณ ๊ฐ๋งŒ์กฑ๋„์™€ ์œ ์˜๋ฏธํ•œ ์ •(+)์˜ ์ƒ๊ด€๊ด€๊ณ„๊ฐ€ ์žˆ์Œ์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ด๋Š” ๋‚ด๋ถ€ ๊ตฌ์„ฑ์›๋“ค์˜ โ€˜์ฒญ๋ ดโ€™ํ•œ ๋งˆ์Œ๊ฐ€์ง๊ณผ ํˆฌ๋ช…ํ•œ ์—…๋ฌด์ฒ˜๋ฆฌ๊ฐ€ ๊ถ๊ทน์ ์œผ๋กœ๋Š” ๊ธฐ์—…์˜ ์™ธ๋ถ€๊ณ ๊ฐ์—๊ฒŒ๊นŒ์ง€ ๊ธ์ •์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค๋Š” ๊ฒƒ์ด๋ผ ์ถ”์ •๋œ๋‹ค ์„ธ ๋ฒˆ์งธ, ์—ฌ์„ฑ์ง์›๋น„์œจ์ด ์ฒญ๋ ด๋„ ์ˆ˜์ค€๊ณผ ๊ธฐ์—…์˜ ๊ฒฝ์˜์„ฑ๊ณผ๊ฐ„ ์ƒ๊ด€๊ด€๊ณ„์— ๋ถ€์ •์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์นœ๋‹ค๋Š” ๊ฒƒ์„ ํ™•์ธํ•˜์˜€๋‹ค. ํŠนํžˆ ์—ฌ์„ฑ์ง์›๋น„์œจ์ด ๋†’์„์ˆ˜๋ก ์ข…ํ•ฉ์ฒญ๋ ด๋„, ๋‚ด๋ถ€์ฒญ๋ ด๋„์™€ ๊ณ ๊ฐ๋งŒ์กฑ๋„๊ฐ„์˜ ๊ด€๊ณ„์— ์žˆ์–ด ๋ถ€์ •์ ์ธ ์˜ํ–ฅ์„ ๊ฐ•ํ•˜๊ฒŒ ํ•˜๊ฑฐ๋‚˜ ๊ธ์ •์ ์ธ ์˜ํ–ฅ์„ ์•ฝํ•˜๊ฒŒ ๋งŒ๋“ ๋‹ค๋Š” ๊ฒƒ์„ ํ™•์ธํ•˜์˜€๋‹ค. ์ด๋Š” ์ด์œค์ถ”๊ตฌ์˜ ๊ทน๋Œ€ํ™”๋ฅผ ์ง€ํ–ฅํ•˜๋Š” ์™ธ๋ถ€๊ณ ๊ฐ์€ ์‹ ์†ํ•˜๊ณ  ์œตํ†ต์„ฑ์žˆ๋Š” ์ผ์ฒ˜๋ฆฌ๋ฅผ ์š”๊ตฌํ•  ๊ฒƒ์ด๊ณ  ๋ถ€ํŒจ์— ๋œ ๊ด€์—ฌ๋˜๋Š” ์—ฌ์„ฑ์ง์›์˜ ํŠน์„ฑ์ƒ ์ ˆ์ฐจ์˜ ์ ๋ฒ•์„ฑ๊ณผ ์ •๋‹น์„ฑ์„ ์ถ”๊ตฌํ•˜์—ฌ ์ด๋Ÿฌํ•œ ๊ณผ์ •์—์„œ ์ถฉ๋Œ์ด ๋ฐœ์ƒํ•˜๊ณ  ์ด๋Š” ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ถ€์ •์ ์ธ ์˜ํ–ฅ์„ ๋ฏธ์ณค๋‹ค๊ณ  ์œ ์ถ”ํ•  ์ˆ˜ ์žˆ๋‹ค. ๋งˆ์ง€๋ง‰์œผ๋กœ ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜•์ด ์ฒญ๋ ด๋„ ์ˆ˜์ค€๊ณผ ๊ธฐ์—…์˜ ๊ฒฝ์˜์„ฑ๊ณผ๊ฐ„ ์ƒ๊ด€๊ด€๊ณ„์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ์— ๋Œ€ํ•ด์„œ๋Š” ํฌ๊ฒŒ ์œ ์˜๋ฏธํ•œ ๊ฒฐ๊ณผ๋ฅผ ์–ป์ง€๋Š” ๋ชปํ•˜์˜€๋‹ค. B2C๊ธฐ์—…์— ๊ฐ€๊นŒ์šธ์ˆ˜๋ก ๋ถˆํŠน์ • ๋‹ค์ˆ˜์˜ ๊ณ ๊ฐ์„ ์ƒ๋Œ€๋กœ ์˜์—…ํ™œ๋™์„ ์˜์œ„ํ•ด์•ผํ•˜๊ณ  ์ด๋Š” ๊ณ ๊ฐ๋งŒ์กฑ๋„ ํ–ฅ์ƒ์„ ์œ„ํ•ด ๊ธฐ์—…์˜ ์ธ์ ยท๋ฌผ์ ์ž์›์„ ์•„๋‚Œ์—†์ด ํˆฌ์žํ•˜์—ฌ ๊ธ์ •์ ์ธ ํšจ๊ณผ๋กœ ๊ท€๊ฒฐ๋  ๊ฒƒ์ด๋ผ๊ณ  ํŒ๋‹จํ•˜์˜€๋Š”๋ฐ ํŠน๋ณ„ํ•œ ์ƒ๊ด€๊ด€๊ณ„๋Š” ์—†๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๊ฒฐ๋ก ์ ์œผ๋กœ ๋†’์€ ์ฒญ๋ ด๋„์ˆ˜์ค€์ด ๋†’์€ ๊ธฐ์—…์˜ ๊ฒฝ์˜์„ฑ๊ณผ๋ฅผ ๋‹ด๋ณดํ•œ๋‹ค๋Š” ๊ฒฐ๊ณผ๋ฅผ ๋„์ถœํ•ด๋‚ด๋Š”๋ฐ๋Š” ์‹คํŒจํ–ˆ์ง€๋งŒ ์ตœ์†Œํ•œ ์ฒญ๋ ด๋„์ˆ˜์ค€์ด ๊ธฐ์—…์˜ ๊ฒฝ์˜์„ฑ๊ณผ์™€ ๋ฌด์˜๋ฏธํ•œ ๊ด€๊ณ„๋Š” ์•„๋‹˜์„ ์ตœ์†Œํ•œ ์ž…์ฆํ–ˆ๋‹ค๋Š” ์ ์—์„œ ๋ณธ ์—ฐ๊ตฌ์˜ ์˜๋ฏธ๊ฐ€ ์žˆ๋‹ค๊ณ  ์ƒ๊ฐํ•œ๋‹ค์ œ 1 ์žฅ ์„œ ๋ก  1 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ฐฐ๊ฒฝ ๋ฐ ๋ชฉ์  1 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ฒ”์œ„ ๋ฐ ๋ฐฉ๋ฒ• 5 ์ œ 2 ์žฅ ์ด๋ก ์  ๋ฐฐ๊ฒฝ ๋ฐ ์„ ํ–‰์—ฐ๊ตฌ ๋ถ„์„ 6 ์ œ 1 ์ ˆ ์ด๋ก ์  ๋ฐฐ๊ฒฝ 6 1. ์œค๋ฆฌ๊ฒฝ์˜์˜ ๊ฐœ๋…๊ณผ ํ•„์š”์„ฑ 6 2. ์œค๋ฆฌ๊ฒฝ์˜์˜ ๊ธฐ๋ณธ์ด๋ก  9 3. ์ฒญ๋ ด, ๋ถ€ํŒจ ๊ทธ๋ฆฌ๊ณ  ์œค๋ฆฌ๊ฒฝ์˜ 12 4. ๊ณต๊ณต๊ธฐ๊ด€์˜ ์ฒญ๋ ด๋„ ์ธก์ • 16 ์ œ 2 ์ ˆ ์„ ํ–‰์—ฐ๊ตฌ ๊ฒ€ํ†  20 1. ์œค๋ฆฌ๊ฒฝ์˜๊ณผ ์žฌ๋ฌด์  ์„ฑ๊ณผ์— ๋Œ€ํ•œ ์„ ํ–‰์—ฐ๊ตฌ ๊ฒ€ํ†  21 2. ์œค๋ฆฌ๊ฒฝ์˜๊ณผ ๋น„์žฌ๋ฌด์  ์„ฑ๊ณผ์— ๋Œ€ํ•œ ์„ ํ–‰์—ฐ๊ตฌ ๊ฒ€ํ†  23 3. ์œค๋ฆฌ๊ฒฝ์˜๊ณผ ๊ฒฝ์˜ํ‰๊ฐ€๊ฒฐ๊ณผ์— ๋Œ€ํ•œ ์„ ํ–‰์—ฐ๊ตฌ ๊ฒ€ํ†  25 4. ๊ธฐ์กด ์—ฐ๊ตฌ์˜ ํ•œ๊ณ„ 26 ์ œ 3 ์žฅ ์—ฐ๊ตฌ ๋ฐฉ๋ฒ• 27 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ถ„์„ํ‹€ 27 ์ œ 2 ์ ˆ ๋ณ€์ˆ˜์˜ ์กฐ์ž‘์  ์ •์˜ 28 1. ๋…๋ฆฝ๋ณ€์ˆ˜์™€ ์ข…์†๋ณ€์ˆ˜ 28 2. ํ†ต์ œ๋ณ€์ˆ˜ 33 3. ์กฐ์ ˆ๋ณ€์ˆ˜ 34 ์ œ 3 ์ ˆ ์—ฐ๊ตฌ๊ฐ€์„ค 37 ์ œ 4 ์ ˆ ์ž๋ฃŒ์ˆ˜์ง‘ ๋ฐ ๋ถ„์„๋ฐฉ๋ฒ• 40 1. ์ž๋ฃŒ์˜ ์ˆ˜์ง‘ 40 2. ์ž๋ฃŒ๋ถ„์„ ๊ธฐ๋ฒ• 40 ์ œ 4 ์žฅ ์—ฐ๊ตฌ์˜ ๋ถ„์„๊ฒฐ๊ณผ 41 ์ œ 1 ์ ˆ ๊ธฐ์ˆ ์  ํ†ต๊ณ„๋ถ„์„ 41 1. ๋…๋ฆฝ๋ณ€์ˆ˜ 41 2. ์ข…์†๋ณ€์ˆ˜ 41 3. ํ†ต์ œ๋ณ€์ˆ˜ 42 4. ์กฐ์ ˆ๋ณ€์ˆ˜ 43 ์ œ 2 ์ ˆ ๋‹ค์ค‘ํšŒ๊ท€๋ถ„์„์„ ํ†ตํ•œ ๊ฐ€์„ค๊ฒ€์ • 43 1. ๋‹ค์ค‘๊ณต์„ ์„ฑ ๋ถ„์„ 43 2. ์ด๊ด„๋ถ„์„ ๊ฒฐ๊ณผ 48 ์ œ 3 ์ ˆ ๋ถ„์„๊ฒฐ๊ณผ ํ•ด์„ 93 1. ์™ธ๋ถ€์ฒญ๋ ด๋„ ์ˆ˜์ค€์ด ๊ณต๊ธฐ์—… ๊ฒฝ์˜์„ฑ๊ณผ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ 95 2. ๋‚ด๋ถ€์ฒญ๋ ด๋„ ์ˆ˜์ค€์ด ๊ณต๊ธฐ์—… ๊ฒฝ์˜์„ฑ๊ณผ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ 96 2. ์—ฌ์„ฑ์ง์›๋น„์œจ, ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜•์˜ ์กฐ์ ˆํšจ๊ณผ 97 ์ œ 5 ์žฅ ๊ฒฐ๋ก  99 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ๊ฒฐ๊ณผ ์š”์•ฝ 99 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ๊ฒฐ๊ณผ์˜ ์ •์ฑ…์  ํ•จ์˜ 103 ์ œ 3 ์ ˆ ์—ฐ๊ตฌ์˜ ํ•œ๊ณ„ 104 Abstract 106 ์ฐธ๊ณ ๋ฌธํ—Œ 109 ํ‘œ ๋ชฉ์ฐจ 3 [ํ‘œ1] 2020๋…„๋„ OECD ๊ตญ๊ฐ€ ๋ถ€ํŒจ์ธ์‹์ง€์ˆ˜ 3 [ํ‘œ2] ์œค๋ฆฌ์  ์˜์‚ฌ๊ฒฐ์ •์— ์‚ฌ์šฉ๋˜๋Š” ์œค๋ฆฌ์ฒ ํ•™๊ณผ ํŒ๋‹จ๊ธฐ์ค€ 10 [ํ‘œ3] ๊ณต๊ณต๊ธฐ๊ด€ ์œ ํ˜•๋ถ„๋ฅ˜ 19 [ํ‘œ4] ๊ณต๊ณต๊ธฐ๊ด€ ์ง€์ •ํ˜„ํ™ฉ 20 [ํ‘œ5] ์™ธ๋ถ€์ฒญ๋ ด๋„ ์„ธ๋ถ€์ธก์ •ํ•ญ๋ชฉ ํ˜„ํ™ฉ 30 [ํ‘œ6] ๋‚ด๋ถ€์ฒญ๋ ด๋„ ์„ธ๋ถ€์ธก์ •ํ•ญ๋ชฉ ํ˜„ํ™ฉ 31 [ํ‘œ7] ๋ณ€์ˆ˜์˜ ์กฐ์ž‘์  ์ •์˜(๋…๋ฆฝ๋ณ€์ˆ˜, ์ข…์†๋ณ€์ˆ˜) 35 [ํ‘œ8] ๋ณ€์ˆ˜์˜ ์กฐ์ž‘์  ์ •์˜(ํ†ต์ œ๋ณ€์ˆ˜) 35 [ํ‘œ9] ๋ณ€์ˆ˜์˜ ์กฐ์ž‘์  ์ •์˜(์กฐ์ ˆ๋ณ€์ˆ˜) 36 [ํ‘œ10] ๋…๋ฆฝ๋ณ€์ˆ˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 41 [ํ‘œ11] ์ข…์†๋ณ€์ˆ˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 42 [ํ‘œ12] ํ†ต์ œ๋ณ€์ˆ˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 42 [ํ‘œ13] ์กฐ์ ˆ๋ณ€์ˆ˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 43 [ํ‘œ14] ํ”ผ์–ด์Šจ ์ƒ๊ด€๊ณ„์ˆ˜ 45 [ํ‘œ15] ๋ถ„์‚ฐํŒฝ์ฐฝ์ง€์ˆ˜(VIF)์™€ ๊ณต์ฐจํ•œ๊ณ„ 46~ 47 [ํ‘œ16] ์ฒญ๋ ด๋„์ˆ˜์ค€, ๊ฒฝ์˜์„ฑ๊ณผ ๋ฐ ์กฐ์ ˆํšจ๊ณผ ๋ถ„์„๊ฒฐ๊ณผ 48 [ํ‘œ17] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ  ๋ถ„์„๊ฒฐ๊ณผ 49 [ํ‘œ18] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ ๋ถ„์„๊ฒฐ๊ณผ 50 [ํ‘œ19] ์ด์ž์‚ฐํšŒ์ „์œจ ๋ถ„์„๊ฒฐ๊ณผ 51 [ํ‘œ20] ๊ณ ๊ฐ๋งŒ์กฑ๋„ ๋ถ„์„๊ฒฐ๊ณผ 53 [ํ‘œ21] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 55 [ํ‘œ22] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 56 [ํ‘œ23] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 58 [ํ‘œ24] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 58 [ํ‘œ25] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 61 [ํ‘œ26] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 63 [ํ‘œ27] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 64 [ํ‘œ28] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 66 [ํ‘œ29] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 68 [ํ‘œ30] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 69 [ํ‘œ31] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 71 [ํ‘œ32] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ์—ฌ์„ฑ์ง์›๋น„์œจ ์กฐ์ ˆํšจ๊ณผ 73 [ํ‘œ33] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 74 [ํ‘œ34] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 76 [ํ‘œ35] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 77 [ํ‘œ36] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 79 [ํ‘œ37] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 81 [ํ‘œ38] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 82 [ํ‘œ39] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 84 [ํ‘œ40] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 85 [ํ‘œ41] ๋งค์ถœ์•ก์„ธ์ „์ด์ต๋ฅ ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 87 [ํ‘œ42] ์ด์ž๋ณด์ƒ๋ฐฐ์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 89 [ํ‘œ43] ์ด์ž์‚ฐํšŒ์ „์œจ์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 90 [ํ‘œ44] ๊ณ ๊ฐ๋งŒ์กฑ๋„์— ๋ฏธ์น˜๋Š” ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜• ์กฐ์ ˆํšจ๊ณผ 92 [ํ‘œ45] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€ 93 [ํ‘œ46] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€(์กฐ์ ˆํšจ๊ณผ, ์—ฌ์„ฑ์ง์›๋น„์œจ) 94 [ํ‘œ47] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€(์กฐ์ ˆํšจ๊ณผ, ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜•) 95 [ํ‘œ48] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€ 99 [ํ‘œ49] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€(์กฐ์ ˆํšจ๊ณผ, ์—ฌ์„ฑ์ง์›๋น„์œจ) 100 [ํ‘œ50] ๊ฐ€์„ค์ฑ„ํƒ์—ฌ๋ถ€(์กฐ์ ˆํšจ๊ณผ, ๊ณ ๊ฐํŠน์„ฑ๋ณ„๊ธฐ์—…์œ ํ˜•) 100 ๊ทธ๋ฆผ ๋ชฉ์ฐจ 3 [๊ทธ๋ฆผ1] ์šฐ๋ฆฌ๋‚˜๋ผ CPI ๋ณ€๋™์ถ”์ด 3 [๊ทธ๋ฆผ2] ์ข…ํ•ฉ์ฒญ๋ ด๋„ ์ ์ˆ˜์ถ”์ด 16 [๊ทธ๋ฆผ3] ์ข…ํ•ฉ์ฒญ๋ ด๋„ ๋ฐ ์˜์—ญ๋ณ„ ์ ์ˆ˜๋น„๊ต 17 [๊ทธ๋ฆผ4] ๋‚ด์™ธ๋ถ€์ฒญ๋ ด๋„ ๋ถ€ํŒจ๊ฒฝํ—˜๋ฅ  17 [๊ทธ๋ฆผ5] 2021๋…„ ๊ณต๊ณต๊ธฐ๊ด€ ์ฒญ๋ ด๋„ ์ธก์ •๋ชจ๋ธ 18 [๊ทธ๋ฆผ6] ์—ฐ๊ตฌ๋ถ„์„ํ‹€ 27 [๊ทธ๋ฆผ7] ๊ตญ๋ฏผ๊ถŒ์ต์œ„์›ํšŒ 2021๋…„๋„ ์ฒญ๋ ด๋„ ์ธก์ •๋ชจ๋ธ 29 [๊ทธ๋ฆผ8] ์™ธ๋ถ€์ฒญ๋ ด๋„ ์ธก์ •๋ชจํ˜• 30์„

    Resource Allocation Algorithm for Differentiated Multimedia Services Using Game Theory

    Get PDF
    ๋ณธ ๋…ผ๋ฌธ์€ 2008๋…„๋„ ํ•œ๊ตญ๊ฒฝ์˜๊ณผํ•™ํšŒ ์ถ”๊ณ„ํ•™์ˆ ๋Œ€ํšŒ ๊ฒฝ์Ÿ๋ถ€๋ฌธ(์ด๋ก ) ์ˆ˜์ƒ๋…ผ๋ฌธ์œผ๋กœ ์†Œ์ •์˜ ์‹ฌ์‚ฌ๊ณผ์ •์„ ๊ฑฐ์ณ ๊ฒŒ์žฌ ์ถ”์ฒœ๋˜์—ˆ์Œ.Game theory is adapted to a variety of domains such as economics, biology, engineering, political science, computer science, and philosophy in order to analyze economic behaviors. This research is an application of game theory to wireless communication. In particular, in terms of bargaining game we dealt with a multimedia resource allocation problem in wireless communication, which is rapidly spreading such as Wibro, WCDML, IPTV, etc. The algorithm is assumed to allocate multimedia resources to users who can choose and access differentiated media services. For this purpose, a utility function of users is devised to reflect quality of service (QoS) and price. We illustrated experimental results with synthesis data which were made to mimic real multimedia data, and analyzed differentiated service providing and the effect of the utility function.๋ณธ ์—ฐ๊ตฌ๋Š” ์ง€์‹๊ฒฝ์ œ๋ถ€ ๋ฐ ์ •๋ณดํ†ต์‹  ์—ฐ๊ตฌ์ง„ํฅ์›์˜ IT์›์ฒœ๊ธฐ์ˆ ๊ฐœ๋ฐœ์‚ฌ์—…(IITA-2008-F-005-01)์˜ ์ง€์›์œผ๋กœ ์ˆ˜ํ–‰๋˜์—ˆ์Œ

    A Study of the treatment of acne vulgaris using dual mode 1064-nm Nd:YAG laser assisted with a topical carbon

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜ํ•™๊ณผ ํ”ผ๋ถ€๊ณผํ•™์ „๊ณต, 2011.2. ์„œ๋Œ€ํ—Œ.Maste

    ํŒจํ˜ˆ์ฆ ์ค‘์ฆ๋„์— ๋”ฐ๋ฅธ Hemopexin ํ˜ˆ์ค‘ ๋†๋„์˜ ๋ณ€ํ™”์— ๊ด€ํ•œ ์ž„์ƒ ๋ฐ ์ „ ์ž„์ƒ ์—ฐ๊ตฌ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์˜ํ•™๊ณผ, 2012. 2. ๊ณฝ์˜ํ˜ธ.๋ฐฐ๊ฒฝ: ํŒจํ˜ˆ์ฆ์€ ๊ฐ์—ผ์— ์˜ํ•œ ์ „์‹  ์—ผ์ฆ๋ฐ˜์‘์„ ์กฐ์ ˆ ํ•˜์ง€ ๋ชปํ•˜๊ณ  ์กฐ์ง์˜ ์†์ƒ์„ ์œ ๋ฐœํ•˜๋Š” ๋ณ‘์ ์ธ ์ƒํƒœ๋ฅผ ๋งํ•œ๋‹ค. ํŒจํ˜ˆ์ฆ์˜ ์ •ํ™•ํ•œ ๊ธฐ์ „์€ ์•„์ง ๋ฐํ˜€์ง€์ง€ ์•Š์•˜์œผ๋‚˜ ์—ฌ๋Ÿฌ ์—ฐ๊ตฌ๋“ค์— ์˜ํ•˜๋ฉด ํŒจํ˜ˆ์ฆ์€ ๊ฐ์ข… ์—ผ์ฆ์„ฑ ๋ฌผ์งˆ๋“ค์— ์˜ํ•˜์—ฌ ๋Œ€์‚ฌ ๊ณผ์ •, ์กฐ์ง ์ด ์†์ƒ๋˜๊ณ  ์ด๋กœ ์ธํ•œ ๋‹ค๊ธฐ๊ด€ ์†์ƒ์„ ์œ ๋ฐœํ•œ๋‹ค๊ณ  ์•Œ๋ ค์ ธ ์žˆ๋‹ค. Heme์€ ํ˜ˆ์ค‘์— ๋…ธ์ถœ ๋˜์—ˆ์„ ๋•Œ ๊ฐ•๋ ฅํ•œ pro-oxidant๋กœ ์ž‘์šฉํ•˜๋ฉฐ ํŠนํžˆ ํŒจํ˜ˆ์ฆ ์ƒํ™ฉ์—์„œ ์—ผ์ฆ์„ฑ ๋ฌผ์งˆ๋“ค๊ณผ ๊ณต์กดํ•ด ์žˆ๋Š” ๊ฒฝ์šฐ์— ์กฐ์ง์†์ƒ์„ ๋”์šฑ ๊ฐ€์†ํ™” ์‹œํ‚จ๋‹ค๊ณ  ์•Œ๋ ค์ ธ ์žˆ๋‹ค. Hemopexin์€ ํ˜ˆ์ค‘ Heme๊ณผ ๊ฒฐํ•ฉํ•˜์—ฌ heme์„ ์ œ๊ฑฐํ•ด ์ฃผ๋Š” ๋ฌผ์งˆ๋กœ ํŒจํ˜ˆ์ฆ ์ƒํ™ฉ์—์„œ hemopexin์˜ ํ˜ˆ์ค‘ ๋†๋„๊ฐ€ ํ™˜์ž์˜ ์‚ฌ๋ง๋ฅ ๊ณผ ์—ฐ๊ด€์ด ์žˆ๋‹ค๋Š” ์—ฐ๊ตฌ๋“ค์ด ์žˆ์œผ๋‚˜ ์•„์ง ๊ทผ๊ฑฐ๊ฐ€ ๋ถ€์กฑํ•˜๋‹ค๊ณ  ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ๋ชฉ์  : ์ž„์ƒ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•˜์—ฌ ํŒจํ˜ˆ์ฆ ์‡ผํฌ ํ™˜์ž์—์„œ ํ˜ˆ์ค‘ hemopexin ๋†๋„์™€ 28์ผ ์ƒ์กด์œจ๊ณผ์˜ ๊ด€๊ณ„๋ฅผ ํ™•์ธํ•˜๊ณ  ์ „ ์ž„์ƒ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•˜์—ฌ ๋ฐฑ์„œ์˜ ํŒจํ˜ˆ์ฆ ๋ชจ๋ธ์—์„œ ํŒจํ˜ˆ์ฆ์˜ ์ค‘์ฆ๋„์— ๋”ฐ๋ผ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ํ˜ˆ์ค‘ hemopexin ๋†๋„์˜ ๋ณ€ํ™”์— ์ฐจ์ด๊ฐ€ ์žˆ๋Š” ์ง€๋ฅผ ํ™•์ธํ•˜๊ณ ์ž ํ•˜์˜€๋‹ค. ๋ฐฉ๋ฒ•: 1. ์ž„์ƒ ์—ฐ๊ตฌ :ใ€€์ „ํ–ฅ์  ์ฝ”ํ˜ธํŠธ ๋ฐฉ๋ฒ•์œผ๋กœ 2006๋…„ 2์›”๋ถ€ํ„ฐ 2010๋…„ 5์›”๊นŒ์ง€ ์„œ์šธ๋Œ€ํ•™๊ต๋ณ‘์› ์‘๊ธ‰์ค‘ํ™˜์ž์‹ค์— ์ž…์›ํ•œ ํŒจํ˜ˆ์ฆ ์‡ผํฌ ํ™˜์ž๋ฅผ ๋Œ€์ƒ์œผ๋กœ ํ•˜์˜€์œผ๋ฉฐ ์ด ๋“ค์˜ ๊ธฐ๋ณธ์ ์ธ ์ธ์ ์‚ฌํ•ญ๊ณผ ์ง„๋‹จ๋ช…, APACHE II ์ ์ˆ˜์™€ ํ˜ˆ์ค‘ ์ –์‚ฐ ๋†๋„์— ๋Œ€ํ•œ ์ž๋ฃŒ๋ฅผ ์ˆ˜์ง‘ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ ๋Œ€์ƒ์ž๋“ค์˜ 28์ผ ์ƒ์กด์„ ํ™•์ธํ•˜๊ณ  28์ผ ์ƒ์กด๊ตฐ๊ณผ ์‚ฌ๋ง๊ตฐ์„ ๋‚˜๋ˆ„์—ˆ๊ณ , ๋‘ ๊ตฐ ๊ฐ„์˜ ํ˜ˆ์ค‘ hemopexin ๋†๋„์™€ ์ƒ์กด์œจ์„ ๋น„๊ตํ•˜์˜€์œผ๋ฉฐ, APACHE II ์ ์ˆ˜, lactic acid์™€ ํ˜ˆ์ค‘ hemopexin ๋†๋„ ๊ฐ„์˜ ์ƒ๊ด€๊ด€๊ณ„๋ฅผ ๋ถ„์„ํ•˜์˜€๋‹ค. 2. ์ „ ์ž„์ƒ์—ฐ๊ตฌ :ใ€€์ฒด์ค‘ 300-350g์˜ ์ˆ˜์ปท Sprague-Dawley ๋ฐฑ์„œ๋ฅผ ํ†ตํ•ด ์‹คํ—˜์„ ์ง„ํ–‰ํ•˜์˜€๋‹ค. ๊ฒฝ์ฆ ๋ฐ ์ค‘์ฆ ํŒจํ˜ˆ์ฆ ๋ชจ๋ธ์„ ํ†ตํ•˜์—ฌ ์„ธ ๊ตฐ์œผ๋กœ ๋‚˜๋ˆ„์–ด ์‹คํ—˜ํ•˜์˜€๋‹ค. ๊ฐ€) ๋Œ€์กฐ๊ตฐ(control group, n=6) ๋‚˜) ๊ฒฝ์ฆ ํŒจํ˜ˆ์ฆ ๊ตฐ(LGS group, n = 18), ๋‚˜) ์ค‘์ฆ ํŒจํ˜ˆ์ฆ ๊ตฐ (HGS group, n = 20)์ด๋ฉฐ ๋Œ€์กฐ๊ตฐ์€ ์ƒ๋ฆฌ์‹์—ผ์ˆ˜๋ฅผ ๊ผฌ๋ฆฌ์ •๋งฅ์„ ํ†ตํ•ด ์ฃผ์ž…ํ•˜๊ณ , LGS ๊ตฐ์€ 5mg/kg์˜ LPS๋ฅผ ๊ผฌ๋ฆฌ์ •๋งฅ์„ ํ†ตํ•ด ์ฃผ์ž…ํ•˜์˜€์œผ๋ฉฐ, HGS ๊ตฐ์€ ๊ฐ™์€ ๋ฐฉ๋ฒ•์œผ๋กœ 10mg/kg์˜ LPS๋ฅผ ์ฃผ์ž…ํ•˜์˜€๋‹ค. LPS ์ฃผ์ž… ํ›„ 1์‹œ๊ฐ„, 3์‹œ๊ฐ„, 6์‹œ๊ฐ„ ๊ฒฝ๊ณผ ํ›„์— ๊ฐ ์‹œ๊ฐ„๋ณ„ 6 ๋งˆ๋ฆฌ์”ฉ์˜ ๋ฐฑ์„œ๋ฅผ ์•ˆ๋ฝ์‚ฌ ์‹œ์ผœใ€€ํ˜ˆ์ค‘ hemopexin์˜ ๋†๋„์™€ TNF-a, IL-6๋ฅผ ์ธก์ •ํ•˜์˜€๋‹ค. ๊ฒฐ๊ณผ: 1. ์ž„์ƒ์—ฐ๊ตฌ : ์ด 142๋ช…์˜ ํ™˜์ž๊ฐ€ ํฌํ•จ๋˜์—ˆ๊ณ  ์ด์ค‘ 100๋ช…์€ ์ƒ์กด๊ตฐ, 42๋ช…์€ ์‚ฌ๋ง๊ตฐ์ด์—ˆ๋‹ค. ์ž…์›๋‹น์‹œ APACHE II ์ ์ˆ˜์™€ ์ –์‚ฐ ๋†๋„๋Š” ์‚ฌ๋ง๊ตฐ์—์„œ ์œ ์˜ํ•˜๊ฒŒ ๋†’์•˜์œผ๋ฉฐ, (๊ฐ๊ฐ p < 0.001, p < 0.001) ์ดˆ๊ธฐ ํ˜ˆ์ค‘ hemopexin ๋†๋„๋Š” ์‚ฌ๋ง๊ตฐ์—์„œ ์ƒ์กด๊ตฐ์— ๋น„ํ•ด ๋‚ฎ์•˜๋‹ค. (p < 0.001) hemopexin ๋†๋„์˜ AUC๋Š” 0.754 (95% ์‹ ๋ขฐ๊ตฌ๊ฐ„, 0.670-0.839) ์˜€๊ณ , ๋‹ค๋ณ€๋Ÿ‰ ๋ถ„์„ ๊ฒฐ๊ณผ ํ˜ˆ์ค‘ hemopexin์˜ ๋†๋„์™€ ์‚ฌ๋ง๋ฅ  ์‚ฌ์ด์—๋Š” ์—ญ์˜ ์ƒ๊ด€๊ด€๊ณ„๋ฅผ ๋ณด์˜€๋‹ค. (p = 0.032) 2. ์ „ ์ž„์ƒ์—ฐ๊ตฌ : ๋ฐฑ์„œ ํŒจํ˜ˆ์ฆ ๋ชจ๋ธ์—์„œ LGS ๊ตฐ๊ณผ HGS ๊ตฐ ๊ฐ„์˜ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ํ˜ˆ์ค‘ hemopexin ๋†๋„์˜ ๋ณ€ํ™”์— ์œ ์˜ํ•œ ์ฐจ์ด๊ฐ€ ์žˆ์—ˆ๊ณ  (p = 0.013), ํŠนํžˆ 6์‹œ๊ฐ„ ์งธ HGS๊ตฐ์—์„œ LGS ๊ตฐ์— ๋น„ํ•ด ํ˜ˆ์ค‘ hemopexin ๋†๋„๊ฐ€ ๋‚ฎ์•˜๋‹ค. (p = 0.002) TNF-ฮฑ ์˜ ๋†๋„ ์—ญ์‹œ LGS ๊ตฐ๊ณผ HGS ๊ตฐ ๊ฐ„์˜ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ํ˜ˆ์ค‘ ๋†๋„ ๋ณ€ํ™”์— ์ฐจ์ด๊ฐ€ ์žˆ์—ˆ๊ณ  (P < 0.001), 3, 6์‹œ๊ฐ„ ์งธ HGS ๊ตฐ์—์„œ TNF-ฮฑ์˜ ๋†๋„๊ฐ€ ๋†’์•˜๋‹ค. (p = 0.002 3h, p = 0.002 6h) ๋˜ํ•œ IL-6์˜ ๋†๋„๋Š” LGS ๊ตฐ๊ณผ HGS ๊ตฐ ๊ฐ„์˜ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ํ˜ˆ์ค‘ ๋†๋„ ๋ณ€ํ™”์— ์ฐจ์ด๊ฐ€ ์žˆ์—ˆ๊ณ  (p < 0.001), ๋ชจ๋“  ์‹œ๊ฐ„์—์„œ HGS ๊ตฐ์˜ IL-6 ๋†๋„๊ฐ€ ๋†’์•˜๋‹ค. (p = 0.026 1h, p = 0.026 3h, p = 0.002 6h) ๊ฒฐ๋ก : ํŒจํ˜ˆ์ฆ ์‡ผํฌ ํ™˜์ž์—์„œ ์ดˆ๊ธฐ ํ˜ˆ์ค‘ hemopexin ๋†๋„๊ฐ€ ๋‚ฎ์„ ์ˆ˜๋ก 28์ผ ์‚ฌ๋ง๋ฅ ์ด ์œ ์˜ํ•˜๊ฒŒ ๋†’์•˜๋‹ค. ๋™๋ฌผ ์‹คํ—˜์—์„œ๋„ ํŒจํ˜ˆ์ฆ์˜ ์ค‘์ฆ๋„์— ๋”ฐ๋ผ ์‹œ๊ฐ„์— ๋”ฐ๋ฅธ ํ˜ˆ์ค‘ hemopexin ๋†๋„์˜ ๋ณ€ํ™”์— ์œ ์˜ํ•œ ์ฐจ์ด๊ฐ€ ์žˆ์—ˆ์œผ๋ฉฐ ํŠนํžˆ LPS ํˆฌ์—ฌ 6์‹œ๊ฐ„ ํ›„์˜ ํ˜ˆ์ค‘ hemopexin ๋†๋„๋Š” ์ค‘์ฆ ํŒจํ˜ˆ์ฆ ๊ตฐ์—์„œ ๊ฒฝ์ฆ ํŒจํ˜ˆ์ฆ ๊ตฐ์— ๋น„ํ•ด ์œ ์˜ํ•˜๊ฒŒ ๋‚ฎ์•˜๋‹ค.Maste

    ์‹คํ–‰์‹œ๊ฐ„์บก์Šํ™”๋ฅผ ์ด์šฉํ•œ ๊ฐ์ฒด์ง€ํ–ฅ ์›Œํฌํ”Œ๋กœ์šฐ๊ด€๋ฆฌ์‹œ์Šคํ…œ์˜ ๊ตฌ์ถ•

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์‚ฐ์—…๊ณตํ•™๊ณผ,2001.Maste

    ํ†ตํ•ฉ ๋ณด์•ˆ ๊ด€๋ฆฌ ์‹œ์Šคํ…œ์˜ ์„ค๊ณ„ ๋ฐ ๊ตฌํ˜„

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์ „๊ธฐยท์ปดํ“จํ„ฐ๊ณตํ•™๋ถ€,2003.Maste

    ํ”„๋กœ์„ธ์Šค ์ฝ”๋ ˆ์˜ค๊ทธ๋ž˜ํ”ผ ๋ฐ ํด๋Ÿฌ์Šคํ„ฐ๋ง์„ ์ด์šฉํ•œ ๊ธฐ์—…๊ฐ„ ํ˜‘์—… ํ”„๋กœ์„ธ์Šค์˜ ์„ค๊ณ„์™€ ๋ถ„์„

    No full text
    Thesis(doctoral)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์‚ฐ์—…๊ณตํ•™๊ณผ,2005.Docto

    Construction of 8-membered rings by internal enolate alkylation ๋ถ„์ž๋‚ด enolate๋ฐ˜์‘์„ ํ†ตํ•œ 8ํ™˜ ๊ณ ๋ฆฌ ํ™”ํ•ฉ๋ฌผ์˜ ํ•ฉ์„ฑ์— ๊ด€ํ•œ ์—ฐ๊ตฌ

    No full text
    Thesis (master`s)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์•ฝํ•™๊ณผ ์•ฝํ™”ํ•™์ „๊ณต,2002.Maste
    • โ€ฆ
    corecore